查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
電腦模擬藥物發現市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按組件、工作流程、軟體類型、技術、治療領域、最終用戶、公司和地區細分
市場調查報告書
商品編碼
1321044

電腦模擬藥物發現市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按組件、工作流程、軟體類型、技術、治療領域、最終用戶、公司和地區細分

In Silico Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Workflow, By Software Type, By Technology, By Therapeutic Area, By End User, By Company and By Region
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計在2023年至2027年的預測期內，全球電腦模擬藥物發現市場將出現令人印象深刻的成長。主要因素包括各種疾病發病率的增加、雲端基礎應用程式的使用增加以及技術的廣泛發展，這些都抑制了市場的成長。如今，電腦方法成為藥物發現過程的重要組成部分。這主要是因為它對整個藥物開發軌跡的影響，識別和發現新的潛在藥物，同時大幅減少成本和時間。支持市場成長的其他因素包括廣泛的研究和開發、各種疾病的流行、大量的臨床試驗、越來越重視減少醫療錯誤和再入院率、各種投資、公司之間的合作數量不斷增加以及藥物發現資料量。

雲端基礎應用程式的採用不斷增加

雲端應用程式的使用不斷增加，推動了電腦模擬藥物發現市場的成長。雲端運算使製藥研究人員能夠使用幾乎無限的計算資源，允許他們擴大或縮小其計算環境。雲端運算不僅提高了整體生產力，還最大限度地減少了臨床失敗的機會。例如，2020年，Bristol大學的研究人員聲稱使用雲端基礎解決方案成功解釋了一種名為 ADDomer 的潛在預防性干涉措施的結構。

技術進步支撐市場

計算生物學領域的快速技術進步推動全球電腦模擬藥物發現市場的成長。計算技術在新型藥物化合物的開發中非常有效。技術的進步簡化測序的各個步驟，因此獲得的結果更快、更準確。例如，2021年，輝瑞公司 (Pfizer Inc.) 和亞馬遜網路服務 (AWS) 已批准合作開發雲端基礎新型技術，這些技術可以使臨床試驗中新藥的研究、製造和傳播方式現代化。同樣，2022年，Insilico Medicine 和蘇黎世大學合作，利用 Insilico 的動態人工智慧技術來發現新的胱氨酸病治療方法。

增加投資和合作

隨著各種疾病發生率的增加，對藥物發現和開發的大量投資推動市場的成長。例如，2021年，根據美國藥物研究和製造商協會（PhRMA）發布的一份報告，生物製藥公司在過去十年中在研發方面的投資超過一兆美元，其中2020年創下了創紀錄的一年，當時PhRMA成員行業僅投資約910億美元。此外，人工智慧初創企業與領先研究中心建立的合作夥伴關係越來越多，可能會提供替代指標。例如，2019年，作為2017年與 GSK 開始的 3300 萬英鎊合作夥伴關係的一部分，Exscientia 提供了一種針對慢性阻塞性肺疾病治療的先導分子。

市場細分

全球電腦模擬藥物發現市場分為組件、工作流程、軟體類型、技術、治療領域、最終用戶和公司。根據組件，市場分為軟體、軟體即服務和諮詢即服務。根據工作流程，市場分為發現、臨床前測試和臨床試驗。基於這一發現，市場進一步細分為目標識別、目標驗證和先導化合物發現。根據軟體類型，市場分為分子建模和從頭藥物設計軟體以及藥效團建模軟體。根據技術，市場分為人工智慧、圖形處理單元等。根據治療領域，市場分為人類免疫缺陷病毒（HIV）、傳染病、代謝性疾病、腫瘤疾病等。根據最終用戶，市場分為生物技術和製藥公司、契約研究組織、學術和研究組織等。就國家而言，由於美國廣泛的技術發展，預計在預測期內美國將成為一個利潤豐厚的市場。

市場參與者

Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.), Curia Global, Inc. (Albany Molecular Research Inc.), Charles River Laboratories International, Inc., Chemical Computing Group ULC. (CCG), Collaborative Drug Discovery Inc. (CDD), e-therapeutics plc., Dassault Systemes SE, Insilico Medicine, Inc., Numerate, Inc. 和 Schrodinger, Inc. 是市場上營運的一些領先公司。

可用的客製化

根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。本報告可以使用以下自定義選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球電腦模擬藥物發現市場的影響

第5章：客戶之聲

第6章：全球電腦模擬藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按組件（軟體、軟體即服務、諮詢即服務）
    • 按工作流程（發現、臨床前測試、臨床試驗）
    • 按軟體類型（分子建模和De Novo藥物設計軟體、藥效基團建模軟體）
    • 按技術（人工智慧、圖形處理單元、其他）
    • 按治療領域（人類免疫缺乏病毒 (HIV)、傳染病、代謝紊亂、腫瘤疾病、其他）
    • 按最終用戶（生物技術和製藥公司、契約研究組織、學術和研究組織、其他）
    • 按公司分類 (2021)
    • 按地區
  • 市場地圖

第7章：北美電腦模擬藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按組件（軟體、軟體即服務、諮詢即服務）
    • 按工作流程（發現、臨床前測試、臨床試驗）
    • 按軟體類型（分子建模和De Novo藥物設計軟體、藥效基團建模軟體）
    • 按技術（人工智慧、圖形處理單元、其他）
    • 按治療領域（人類免疫缺乏病毒 (HIV)、傳染病、代謝紊亂、腫瘤疾病、其他）
    • 按最終用戶（生物技術和製藥公司、契約研究組織、學術和研究組織、其他）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第8章：歐洲電腦模擬藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按組件（軟體、軟體即服務、諮詢即服務）
    • 按工作流程（發現、臨床前測試、臨床試驗）
    • 按軟體類型（分子建模和De Novo藥物設計軟體、藥效基團建模軟體）
    • 按技術（人工智慧、圖形處理單元、其他）
    • 按治療領域（人類免疫缺乏病毒 (HIV)、傳染病、代謝紊亂、腫瘤疾病、其他）
    • 按最終用戶（生物技術和製藥公司、契約研究組織、學術和研究組織、其他）
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章：亞太地區電腦模擬藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按組件（軟體、軟體即服務、諮詢即服務）
    • 按工作流程（發現、臨床前測試、臨床試驗）
    • 按軟體類型（分子建模和De Novo藥物設計軟體、藥效基團建模軟體）
    • 按技術（人工智慧、圖形處理單元、其他）
    • 按治療領域（人類免疫缺乏病毒 (HIV)、傳染病、代謝紊亂、腫瘤疾病、其他）
    • 按最終用戶（生物技術和製藥公司、契約研究組織、學術和研究組織、其他）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第10章：南美洲電腦模擬藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按組件（軟體、軟體即服務、諮詢即服務）
    • 按工作流程（發現、臨床前測試、臨床試驗）
    • 按軟體類型（分子建模和De Novo藥物設計軟體、藥效基團建模軟體）
    • 按技術（人工智慧、圖形處理單元、其他）
    • 按治療領域（人類免疫缺乏病毒 (HIV)、傳染病、代謝紊亂、腫瘤疾病、其他）
    • 按最終用戶（生物技術和製藥公司、契約研究組織、學術和研究組織、其他）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲電腦模擬藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市場佔有率及預測
    • 按組件（軟體、軟體即服務、諮詢即服務）
    • 按工作流程（發現、臨床前測試、臨床試驗）
    • 按軟體類型（分子建模和De Novo藥物設計軟體、藥效基團建模軟體）
    • 按技術（人工智慧、圖形處理單元、其他）
    • 按治療領域（人類免疫缺乏病毒 (HIV)、傳染病、代謝紊亂、腫瘤疾病、其他）
    • 按最終用戶（生物技術和製藥公司、契約研究組織、學術和研究組織、其他）
    • 按國家/地區
  • MEA：國家分析
    • 南非電腦模擬藥物發現
    • 沙烏地阿拉伯電腦模擬藥物發現
    • 阿拉伯聯合大公國電腦模擬藥物發現
    • 土耳其電腦模擬藥物發現
    • 埃及電腦模擬藥物發現

第12章：市場動態

  • 促進因素
  • 挑戰

第13章：市場趨勢與發展

第14章：競爭格局

  • Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)
  • Curia Global, Inc. (Albany Molecular Research Inc.)
  • Charles River Laboratories International, Inc.
  • Chemical Computing Group ULC. (CCG)
  • Collaborative Drug Discovery Inc. (CDD)
  • e-therapeutics plc.
  • Dassault Systemes SE
  • Insilico Medicine, Inc.
  • Numerate, Inc.
  • Schrodinger, Inc.

第15章：戰略建議

簡介目錄
Product Code: 13007

The global in silico drug discovery market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include growing incidences of various diseases, rising use of cloud-based applications, and extensive development in technology, which are curbing the market's growth. Nowadays, in silico methodologies are becoming an essential part of the drug discovery process. This is primarily because of the impact on the whole drug development trajectory, identifying and discovering new potential drugs with a substantial reduction in cost and time. The other factors supporting the market's growth are the extensive research and development, prevalence of various diseases, large number of clinical trials, rising emphasis on reduction in medical errors and readmission rates, various investments, the growing number of collaborations between companies, and rise in the volume of drug discovery data.

Rising Adoption of Cloud-Based Applications

The increasing use of cloud applications is fueling the growth of the in-silico drug discovery market. Cloud computing gives access to pharmaceutical researchers to use virtually infinite computational resources, permitting them to scale up or down their computing environment. Cloud computing has not only enhanced overall productivity but also minimized the chances of clinical failure. For instance, in 2020, researchers at the University of Bristol alleged to have used cloud-based solutions to successfully interpret the structure of a potential preventive intervention called ADDomer.

Technological Advancements Support the Market

Rapid technological advancements in the field of computational biology are bolstering the growth of the in-silico drug discovery market globally. Computational techniques are quite effective in the development of novel pharmaceutical compounds. The advancement in technologies is simplifying the various steps in sequencing, due to which the results obtained are faster and more accurate. For instance, in 2021, Pfizer Inc. and Amazon Web Services (AWS) have approved to work together on developing novel cloud-based technologies that could modernize how new medications are studied, manufactured, and disseminated for clinical trials. Similarly, in 2022, Insilico Medicine and the University of Zurich collaborated to leverage Insilico's dynamic AI technology to discover new cystinosis treatments.

Increasing Investments and Collaborations

Heavy investments in drug discovery and development with rising occurrences of various diseases are propelling the growth of the market. For instance, in 2021, as per a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA), biopharmaceutical companies invested more than a trillion dollars in R&D in the last ten years, including a record year in 2020, when PhRMA member industries alone invested approximately 91 billion USD. Furthermore, the increasing number of partnerships that AI start-ups have with leading research centers may offer an alternative metric. For instance, in 2019, as a part of a £33 million partnership with GSK that commenced in 2017, Exscientia delivered a lead molecule targeted at the treatment of chronic obstructive pulmonary disease.

Market Segmentation

The global in silico drug discovery market is segmented into components, workflow, software type, technology, therapeutic area, end user, and company. Based on components, the market is divided into software, software-as-a-service, and consultancy-as-a-service. Based on workflow, the market is divided into discovery, pre-clinical tests, and clinical trials. Based on the discovery, the market is further segmented into target identification, target validation, and lead discovery. Based on software type, the market is segmented into molecular modeling & de novo drug design software and pharmacophore modeling software. Based on technology, the market is segmented into artificial intelligence, graphics processing unit, and others. Based on therapeutic area, the market is segmented into human immunodeficiency virus (HIV), infectious diseases, metabolic disorders, oncology disorders, and others. Based on end users, the market is divided into biotechnology & pharmaceutical companies, contract research organizations, academic & research organizations, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the extensive technology development in the country.

Market Players

Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.), Curia Global, Inc. (Albany Molecular Research Inc.), Charles River Laboratories International, Inc., Chemical Computing Group ULC. (CCG), Collaborative Drug Discovery Inc. (CDD), e-therapeutics plc., Dassault Systemes SE, Insilico Medicine, Inc., Numerate, Inc., and Schrodinger, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global in silico drug discovery market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

In Silico Drug Discovery Market, By Component:

  • Software
  • Software-as-a-Service
  • Consultancy-as-a-Service

In Silico Drug Discovery Market, By Workflow:

  • Discovery
    • Target Identification
    • Target Validation
    • Lead Discovery
  • Pre-Clinical Tests
  • Clinical Trials

In Silico Drug Discovery Market, By Software Type:

  • Molecular Modeling & De Novo Drug Design Software
  • Pharmacophore Modeling Software

In Silico Drug Discovery Market, By Technology:

  • Artificial Intelligence
  • Graphics Processing Unit
  • Others

In Silico Drug Discovery Market, By Therapeutic Area:

  • Human Immunodeficiency Virus (HIV)
  • Infectious Diseases
  • Metabolic Disorders
  • Oncology Disorders
  • Others

In Silico Drug Discovery Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Contract Research Organizations
  • Academic & Research Organizations
  • Others

In Silico Drug Discovery Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global In Silico Drug Discovery Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global In Silico Drug Discovery Market

5. Voice of Customer

6. Global In Silico Drug Discovery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 6.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 6.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 6.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 6.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 6.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 6.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 6.2.7. By Company (2021)
    • 6.2.8. By Region
  • 6.3. Market Map

7. North America In Silico Drug Discovery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 7.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 7.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 7.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 7.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 7.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 7.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States In Silico Drug Discovery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Software Type
        • 7.3.1.2.4. By Technology
        • 7.3.1.2.5. By Therapeutic Area
        • 7.3.1.2.6. By End User
    • 7.3.2. Canada In Silico Drug Discovery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Software Type
        • 7.3.2.2.4. By Technology
        • 7.3.2.2.5. By Therapeutic Area
        • 7.3.2.2.6. By End User
    • 7.3.3. Mexico In Silico Drug Discovery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Software Type
        • 7.3.3.2.4. By Technology
        • 7.3.3.2.5. By Therapeutic Area
        • 7.3.3.2.6. By End User

8. Europe In Silico Drug Discovery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 8.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 8.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 8.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 8.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 8.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 8.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France In Silico Drug Discovery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Software Type
        • 8.3.1.2.4. By Technology
        • 8.3.1.2.5. By Therapeutic Area
        • 8.3.1.2.6. By End User
    • 8.3.2. Germany In Silico Drug Discovery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Software Type
        • 8.3.2.2.4. By Technology
        • 8.3.2.2.5. By Therapeutic Area
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom In Silico Drug Discovery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Software Type
        • 8.3.3.2.4. By Technology
        • 8.3.3.2.5. By Therapeutic Area
        • 8.3.3.2.6. By End User
    • 8.3.4. Italy In Silico Drug Discovery Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Software Type
        • 8.3.4.2.4. By Technology
        • 8.3.4.2.5. By Therapeutic Area
        • 8.3.4.2.6. By End User
    • 8.3.5. Spain In Silico Drug Discovery Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Software Type
        • 8.3.5.2.4. By Technology
        • 8.3.5.2.5. By Therapeutic Area
        • 8.3.5.2.6. By End User

9. Asia-Pacific In Silico Drug Discovery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 9.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 9.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 9.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 9.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 9.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 9.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China In Silico Drug Discovery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Software Type
        • 9.3.1.2.4. By Technology
        • 9.3.1.2.5. By Therapeutic Area
        • 9.3.1.2.6. By End User
    • 9.3.2. India In Silico Drug Discovery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Software Type
        • 9.3.2.2.4. By Technology
        • 9.3.2.2.5. By Therapeutic Area
        • 9.3.2.2.6. By End User
    • 9.3.3. Japan In Silico Drug Discovery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Software Type
        • 9.3.3.2.4. By Technology
        • 9.3.3.2.5. By Therapeutic Area
        • 9.3.3.2.6. By End User
    • 9.3.4. South Korea In Silico Drug Discovery Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Workflow
        • 9.3.4.2.3. By Software Type
        • 9.3.4.2.4. By Technology
        • 9.3.4.2.5. By Therapeutic Area
        • 9.3.4.2.6. By End User
    • 9.3.5. Australia In Silico Drug Discovery Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Workflow
        • 9.3.5.2.3. By Software Type
        • 9.3.5.2.4. By Technology
        • 9.3.5.2.5. By Therapeutic Area
        • 9.3.5.2.6. By End User

10. South America In Silico Drug Discovery Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 10.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 10.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 10.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 10.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 10.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 10.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil In Silico Drug Discovery Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Software Type
        • 10.3.1.2.4. By Technology
        • 10.3.1.2.5. By Therapeutic Area
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina In Silico Drug Discovery Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Software Type
        • 10.3.2.2.4. By Technology
        • 10.3.2.2.5. By Therapeutic Area
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia In Silico Drug Discovery Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Software Type
        • 10.3.3.2.4. By Technology
        • 10.3.3.2.5. By Therapeutic Area
        • 10.3.3.2.6. By End User

11. Middle East and Africa In Silico Drug Discovery Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 11.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 11.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 11.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 11.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 11.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 11.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa In Silico Drug Discovery Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Workflow
        • 11.3.1.2.3. By Software Type
        • 11.3.1.2.4. By Technology
        • 11.3.1.2.5. By Therapeutic Area
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia In Silico Drug Discovery Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Workflow
        • 11.3.2.2.3. By Software Type
        • 11.3.2.2.4. By Technology
        • 11.3.2.2.5. By Therapeutic Area
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE In Silico Drug Discovery Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Workflow
        • 11.3.3.2.3. By Software Type
        • 11.3.3.2.4. By Technology
        • 11.3.3.2.5. By Therapeutic Area
        • 11.3.3.2.6. By End User
    • 11.3.4. Turkey In Silico Drug Discovery Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Workflow
        • 11.3.4.2.3. By Software Type
        • 11.3.4.2.4. By Technology
        • 11.3.4.2.5. By Therapeutic Area
        • 11.3.4.2.6. By End User
    • 11.3.5. Egypt In Silico Drug Discovery Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Workflow
        • 11.3.5.2.3. By Software Type
        • 11.3.5.2.4. By Technology
        • 11.3.5.2.5. By Therapeutic Area
        • 11.3.5.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)
  • 14.2. Curia Global, Inc. (Albany Molecular Research Inc.)
  • 14.3. Charles River Laboratories International, Inc.
  • 14.4. Chemical Computing Group ULC. (CCG)
  • 14.5. Collaborative Drug Discovery Inc. (CDD)
  • 14.6. e-therapeutics plc.
  • 14.7. Dassault Systemes SE
  • 14.8. Insilico Medicine, Inc.
  • 14.9. Numerate, Inc.
  • 14.10. Schrodinger, Inc.

15. Strategic Recommendations